FDA Warns Boehringer About Misleading Mirapex Ads

Law360, New York (October 15, 2008, 12:00 AM EDT) -- German pharmaceutical company Boehringer Ingelheim GmbH misled consumers and doctors about the safety and efficacy of Mirapex, the restless-leg syndrome treatment, according to the U.S. Food and Drug Administration.

The watchdog revealed Tuesday that regulators sent Boehringer a warning letter in September upbraiding the company for disseminating promotional materials that failed to mention the risks associated with Mirapex and overstated its uses.

The pharmaceutical company sent out two consumer-directed printouts for Mirapex that violated the FDA’s labeling laws by omitting the required warnings about the hazards...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.